SCN2A

Sodium channel protein type 2 subunit alpha · Q99250 · SCN2A on Sugi Atlas →

106,058 patent compounds predicted against SCN2A, 69,144 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ambucaine (SCHEMBL82280)	0.91	8/20
Metabutoxycaine (SCHEMBL25778)	0.58	7/20
Propoxycaine (SCHEMBL83073)	1.00	6/20
Propoxycaine (SCHEMBL24720)	0.98	6/20
SCHEMBL85047	0.81	6/20
Biphenamine (SCHEMBL25980)	0.81	6/20
Chloroprocaine (SCHEMBL6676)	0.67	6/20
Benoxinate (SCHEMBL25087)	1.00	5/20
Betoxycaine (SCHEMBL25758)	0.77	5/20
Procaine (SCHEMBL3524)	0.68	5/20
Chloroprocaine (SCHEMBL24096)	0.66	5/20
SCHEMBL517	0.40	5/20
Proparacaine (SCHEMBL23334)	1.00	4/20
SCHEMBL25906	1.00	4/20
SCHEMBL25907	1.00	4/20
Parethoxycaine (SCHEMBL25944)	1.00	4/20
Proparacaine (SCHEMBL23333)	0.98	4/20
Proparacaine (SCHEMBL93880)	0.98	4/20
SCHEMBL25553	0.81	4/20
Hydroquinine (SCHEMBL109600)	0.81	4/20

Clinical trials — most relevant to SCN2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety	PHASE3	RECRUITING
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome	PHASE3	RECRUITING
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies	PHASE2	WITHDRAWN
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)	nan	COMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age	nan	RECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients	nan	COMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Piezo2-related Arthrogryposis & physiopathOLOgy 3	nan	NOT_YET_RECRUITING
Post-stroke Epilepsy: Primary Prophylaxis Study	nan	UNKNOWN
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN2A binder may also engage these)

Protein	Name	Similarity
P04775	—	1.000	P04775 →
SCN3A	Sodium channel protein type 3 subunit alpha	1.000	landscape →
B1AWN6	—	1.000	B1AWN6 →
Q28644	—	1.000	Q28644 →
P08104	—	1.000	P08104 →
Q62205	—	1.000	Q62205 →
A2ASI5	—	1.000	A2ASI5 →
O88420	—	1.000	O88420 →
SCN1A	Sodium channel protein type 1 subunit alpha	1.000	landscape →
A2APX8	—	1.000	A2APX8 →
Q9WTU3	—	1.000	Q9WTU3 →
P15390	—	1.000	P15390 →
SCN9A	Sodium channel protein type 9 subunit alpha	1.000	landscape →
Q62968	—	1.000	Q62968 →
O08562	—	1.000	O08562 →
SCN8A	Sodium channel protein type 8 subunit alpha	1.000	landscape →
P15389	—	1.000	P15389 →
Q6QIY3	—	0.999	Q6QIY3 →
P04774	—	0.999	P04774 →
Q9JJV9	—	0.999	Q9JJV9 →
Q2XVR7	—	0.999	Q2XVR7 →
P02719	—	0.998	P02719 →
Q2XVR6	—	0.998	Q2XVR6 →
Q2XVR3	—	0.998	Q2XVR3 →
SCN5A	Sodium channel protein type 5 subunit alpha	0.997	landscape →
Q20JQ7	—	0.997	Q20JQ7 →
Q9ER60	—	0.997	Q9ER60 →
P35500	—	0.997	P35500 →
SCN10A	Sodium channel protein type 10 subunit alpha	0.996	landscape →
Q28371	—	0.996	Q28371 →